International Journal of Infertility & Fetal Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2024)
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 10 , ISSUE 3 ( September-December, 2019 ) > List of Articles

REVIEW ARTICLE

Prevention and Management of Ovarian Hyperstimulation Syndrome

Deepika Krishna

Citation Information : Krishna D. Prevention and Management of Ovarian Hyperstimulation Syndrome. Int J Infertil Fetal Med 2019; 10 (3):46-51.

DOI: 10.5005/jp-journals-10016-1193

License: CC BY-NC 4.0

Published Online: 10-02-2021

Copyright Statement:  Copyright © 2019; The Author(s).


Abstract

Ovarian hyperstimulation syndrome (OHSS) is a potential iatrogenic life-threatening situation. It is difficult to decipher OHSS pathophysiology.1 The occurrence is directly proportional to estradiol in blood, follicle number, and human chorionic gonadotropin (hCG) with more chances of happening in polycystic ovarian disease. Complete prevention of OHSS is never possible, but endocrine profile and ultrasonographic follicular monitoring are the mainstay of its prediction. Complications such as hemoconcentration, hypovolemia, and thromboembolism can occur. Withholding hCG, continuation of gonadotropin-releasing hormone analogs, coasting, agonist trigger, intravenous albumin, dopamine agonists, and cryopreservation of embryos are cornerstones of OHSS prevention.2 Mild OHSS usually requires no active therapy. Moderate and severe cases have to be treated. Surgery may be needed in ruptured ovarian cysts, torsion, or concomitant ectopic pregnancy. Transvaginal paracentesis is recommended in cases of severe ascites. Inpatient management is typically based on preventing complications such as derangement of kidney and liver functions, thrombosis, and severe respiratory depression. Recent ART treatment protocols behold more patient-friendly mild ovarian stimulation regimes that are individualized depending on patient’s ovarian reserve.3

HTML PDF Share
  1. Prevention of ovarian hyperstimulation syndrome: a review. Obstet Gynecol Int. 2015;2015:514159.
  2. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;94(2):389–400. DOI: 10.1016/j.fertnstert.2010.03.028.
  3. Management ofovarian hyperstimulation syndrome. Produced on behalf of the BFS policy and practice committee. Hum Fertil 2013;16(3):151–159. DOI: 10.3109/14647273.2013.788313.
  4. 5.
  5. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reproduct Bio Med Online 2009;18(2):195–204. DOI: 10.1016/S1472-6483(10)60256-8.
  6. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8(6):559–577. DOI: 10.1093/humupd/8.6.559.
  7. The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. BMC Women's Health 2012;12(1):29. DOI: 10.1186/1472-6874-12-29.
  8. Coexistent hemo concentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril 2000;74(1):67–72. DOI: 10.1016/S0015-0282(00)00573-2.
  9. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol 2009;4(3):299–311. DOI: 10.1586/eog.09.10.
  10. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73(5):901–907. DOI: 10.1016/S0015-0282(00)00492-1.
  11. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147(11):5400–5411. DOI: 10.1210/en.2006-0657.
  12. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3(3):255–266. DOI: 10.1093/humupd/3.3.255.
  13. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71(5):808–814. DOI: 10.1016/S0015-0282(99)00090-4.
  14. Relevance of anti-Mullerian hormone measurement inaroutine IVF program. Hum Reprod 2008;23(6):1359–1365. DOI: 10.1093/humrep/den108.
  15. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014;20(3):370–385. DOI: 10.1093/humupd/dmt062.
  16. Serumanti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23(1):160–167. DOI: 10.1093/humrep/dem254.
  17. Symposium: update on prediction and management of OHSS prevention of OHSS. Reprod Biomed Online 2009;19(1):33–42. DOI: 10.1016/S1472-6483(10)60043-0.
  18. Pulmonary mani festations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1999;71(4):645–651. DOI: 10.1016/S0015-0282(98)00528-7.
  19. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47(3):524–526. DOI: 10.1016/S0015-0282(16)59069-4.
  20. Response of blood coagulation parameters to elevated endogenous 17 beta-estradiol levels induced by human menopausal gonadotropins. Am J Obstet Gynecol 1981;140(7):807–810. DOI: 10.1016/0002-9378(81)90744-4.
  21. Stroke complicating severe ovarian hyperstimulation syndrome. Aust N Z J Med 1992;23(2):219–220. DOI: 10.1111/j.1445-5994.1993.tb01823.x.
  22. Ovarian hyperstimulation syndrome. Report of a case with notes on pathogenesis and treatment. Am J Obstet Gynecol 1972;112(8):1052–1060. DOI: 10.1016/0002-9378(72)90180-9.
  23. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58(2):249–261. DOI: 10.1016/S0015-0282(16)55188-7.
  24. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol 2005;15(2):132–138. DOI: 10.1016/j.curobgyn.2005.01.003.
  25. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999;14(1):167–171. DOI: 10.1093/humrep/14.1.167.
  26. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008;23(2):310–315. DOI: 10.1093/humrep/dem305.
  27. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44(6):430–440. DOI: 10.1097/00006254-198906000-00004.
  28. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil 2007;10(2):75–85. DOI: 10.1080/14647270601111239.
  29. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report. Eur J Obstet Gynecol Reprod Biol 2001;99(1):131–134. DOI: 10.1016/S0301-2115(01)00364-5.
  30. Management of ovarian hyperstimulation syndrome with chlorpheniramine maleate, mannitol, and invasive hemodynamic monitoring. Obstet Gynecol 1988;71:485–487.
  31. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73(5):883–896. DOI: 10.1016/S0015-0282(00)00491-X.
  32. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009;92(3):1168.e1–1168.e4. DOI: 10.1016/j.fertnstert.2009.05.021.
  33. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Reprod Biomed Online 2009;18(Suppl. 2):71–75. DOI: 10.1016/S1472-6483(10)60452-X.
  34. Luteal phase support in infertility treatment: a meta analysis of the randomized trials. Hum Reprod 2002;17(9):2287–2299. DOI: 10.1093/humrep/17.9.2287.
  35. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprodu Update 2003;9(3):275–289. DOI: 10.1093/humupd/dmg018.
  36. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a cochrane review. Hum Reprod 2002;17(12):3027–3032. DOI: 10.1093/humrep/17.12.3027.
  37. A fatal case of ovarian hyperstimulation syndrome with perforated duodenal ulcer. Hum Reprod 2010;25(3):808–809. DOI: 10.1093/humrep/dep434.
  38. Maternal death related to IVF in the Netherlands 1984–2008. Hum Reprod 2010;25(7):1782–1786. DOI: 10.1093/humrep/deq080.
  39. Ovarian salvage in bilaterally complicated severe ovarian hyper stimulation syndrome. Fertil Steril 2011;96(2):e77–e79. DOI: 10.1016/j.fertnstert.2011.06.005.
  40. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 1998;70(4):638–642. DOI: 10.1016/S0015-0282(98)00250-7.
  41. Ovarian hyperstimulation syndrome free IVF clinics. Myth or reality? Int J Gynecol and Reprod Sci 2018;1(1):1–2.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.